Multiple Sclerosis Study
- ALKS 8700: This is a study for MS that guarantees you will receive active medication if eligible. This study is comparing the new medication ALKS 8700 to the market medication, Tecfidera. In this study, patients will receive either a regiment of ALKS 8700 or Tecfidera for about six weeks. After that, there is a choice to enter a long term open label study and continue to receive ALKS 8700. Click the buttons below for more information on the initial study and the open label study. Initial Study / Open Label
At NEICR all of our clinical trials (and procedures associated with them) are completely free. If you are interested in participating or have any questions, feel free to fill out the form below or give us a call at (203) 914-1903 for more information.
Use the form below to enroll